Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
9 steps to validate your life science storage
Good manufacturing practice regulators in Australia have sharpened their focus on life...
Next-gen weight-data integration: cloud, IT and control system connectivity
Discover the latest innovations that can...
How to raise antibody standards and improve reproducibility
Currently 70% of researchers fail to reproduce experiments. With so much research built on...
